Recent Advances of Novel Agents in Clinical Research on Acute Myeloid Leukemia

The treatment of acute myeloid leukemia (AML) has made great progress in recent years. Although the "3+7" induction chemotherapy is still the cornerstone of AML therapy, the emergence of novel agents, including targeted agents such as FLT3 inhibitors, IDH inhibitors, TP53 inhibitors, Bcl-2 inhibitors, SMO inhibitors, antibody-drug conjugates (ADC), immune checkpoint agents, and improved new formulations of traditional drugs have significantly improved the efficacy and survival of patients with AML who are unfit for intensive chemotherapy. Targeted agents combined with intensive regimens can be viable options for salvage therapy and as bridge to allogeneic transplant. In this paper, we reviewed the recent major advances of novel agents in the treatment of AML, aiming to provide the individualized precision strategies and directions for the treatment of AML.